Myofibrillar myopathy 11
diseaseOn this page
Also known as MFM11myopathy, congenital, with eccentric cores
Summary
Myofibrillar myopathy 11 (MONDO:0030927) is a disease caused by UNC45B (GenCC Strong), with 1 cohort gene.
At a glance
- Causal gene: UNC45B (GenCC Strong)
- Cohort genes: 1
- ClinVar variants: 14
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | myofibrillar myopathy 11 |
| Mondo ID | MONDO:0030927 |
| OMIM | 619178 |
| DOID | DOID:0081338 |
| UMLS | C5543038 |
| MedGen | 1782465 |
| GARD | 0025664 |
| Is cancer (heuristic) | no |
Also known as: MFM11 · myopathy, congenital, with eccentric cores
Data availability: 14 ClinVar variants · 4 GenCC gene-disease records.
Disease family
Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › muscle tissue disorder › skeletal muscle disorder › myopathy › congenital myopathy › congenital structural myopathy › myofibrillar myopathy › myofibrillar myopathy 11
Related subtypes (12): central core myopathy, myofibrillar myopathy 1, myofibrillar myopathy 3, myofibrillar myopathy 4, myofibrillar myopathy 5, myofibrillar myopathy 6, fatal infantile hypertonic myofibrillar myopathy, myofibrillar myopathy 7, myofibrillar myopathy 8, myofibrillar myopathy 10, myopathy, myofibrillar, 12, infantile-onset, with cardiomyopathy, myopathy, myofibrillar, 13, with rimmed vacuoles
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
14 retrieved; paginated sample, class counts are floors:
9 uncertain significance, 2 pathogenic, 2 likely pathogenic, 1 benign
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 834072 | NM_001267052.2(UNC45B):c.2255G>A (p.Arg752Gln) | UNC45B | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 996756 | NM_001267052.2(UNC45B):c.1540T>C (p.Cys514Arg) | UNC45B | Pathogenic | no assertion criteria provided |
| 996754 | NM_001267052.2(UNC45B):c.2326C>T (p.Arg776Trp) | UNC45B | Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 996755 | NM_001267052.2(UNC45B):c.2255+5G>C | UNC45B | Likely pathogenic | criteria provided, single submitter |
| 2441785 | NM_001267052.2(UNC45B):c.73G>A (p.Ala25Thr) | UNC45B | Uncertain significance | criteria provided, single submitter |
| 2683907 | NM_001267052.2(UNC45B):c.2293G>A (p.Glu765Lys) | UNC45B | Uncertain significance | criteria provided, single submitter |
| 3186553 | NM_001267052.2(UNC45B):c.1487A>T (p.Asp496Val) | UNC45B | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 3775861 | NM_001267052.2(UNC45B):c.2374G>A (p.Val792Ile) | UNC45B | Uncertain significance | criteria provided, single submitter |
| 3892816 | NM_001267052.2(UNC45B):c.135T>G (p.Leu45=) | UNC45B | Uncertain significance | criteria provided, single submitter |
| 3892817 | NM_001267052.2(UNC45B):c.2408G>A (p.Arg803Gln) | UNC45B | Uncertain significance | criteria provided, single submitter |
| 3892818 | NM_001267052.2(UNC45B):c.2558G>A (p.Arg853Gln) | UNC45B | Uncertain significance | criteria provided, single submitter |
| 3892819 | NM_001267052.2(UNC45B):c.442_443del (p.Glu148fs) | UNC45B | Uncertain significance | criteria provided, single submitter |
| 996753 | NM_001267052.2(UNC45B):c.1207T>C (p.Ser403Pro) | UNC45B | Uncertain significance | criteria provided, single submitter |
| 1220664 | NM_001267052.2(UNC45B):c.808+39G>A | UNC45B | Benign | criteria provided, multiple submitters, no conflicts |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 8 · Orphanet: 2 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
GenCC gene–disease validity (cohort genes)
the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.
| Gene | Classification | Inheritance | Disease | Records |
|---|---|---|---|---|
| UNC45B | Strong | Autosomal recessive | myofibrillar myopathy 11 | 8 |
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| UNC45B | Orphanet:441447 | Early-onset posterior subcapsular cataract |
| UNC45B | Orphanet:98991 | Early-onset nuclear cataract |
Cohort genes → proteins
1 cohort genes, 1 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 1 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| UNC45B | HGNC:14304 | ENSG00000141161 | Q8IWX7 | Protein unc-45 homolog B | gencc,clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| UNC45B | Protein unc-45 homolog B | Acts as a co-chaperone for HSP90 and is required for proper folding of the myosin motor domain. |
Protein-family classification
Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Other/Unknown | 1 | 1.8× | 0.558 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| UNC45B | Other/Unknown | no | Armadillo, ARM-like, TPR-like_helical_dom_sf |
Expression context
Cohort genes with no expression data: 0.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 1 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| cardiac muscle of right atrium | 1 |
| left ventricle myocardium | 1 |
| tibialis anterior | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| UNC45B | 111 | tissue_specific | yes | left ventricle myocardium, cardiac muscle of right atrium, tibialis anterior |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| UNC45B | 1,273 |
Structural data
PDB: 0 · AlphaFold-only: 1 · No structure: 0
AlphaFold-only cohort genes (top 30 by pLDDT)
| Symbol | UniProt | pLDDT |
|---|---|---|
| UNC45B | Q8IWX7 | 88.38 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 0. Enrichment computed across 1 evidence-associated genes (0 with Reactome annotation).
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| lens development in camera-type eye | 1 | 374.5× | 0.011 | UNC45B |
| muscle organ development | 1 | 166.8× | 0.012 | UNC45B |
| protein folding | 1 | 103.4× | 0.013 | UNC45B |
| cell differentiation | 1 | 29.1× | 0.034 | UNC45B |
Therapeutics
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1
Druggability breadth: 0 of 1 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| UNC45B | 0 | 0 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 0.
Pharmacogenomics
Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 1 | UNC45B |
Undrugged target profiles
1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| UNC45B | 0 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
- Cohort genes: UNC45B